Clinical Trial Update: A Study of SGN-B6A Versus Docetaxel in Previously Treated Non-small Cell Lung Cancer [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing SGN-B6A to docetaxel in previously treated non-small cell lung cancer is active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• SGN-B6A

Snippet

Sponsor: Seagen, a wholly owned subsidiary of Pfizer | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: ACTIVE_NOT_RECRUITING